This invention relates to macrostructures (and pharmaceutical formulations containing them) that include a parallel coiled-coil structure, wherein the parallel coiled-coil comprises a first coil of Formula I and a second coil of Formula II:

T.sub.1-f.sub.0-g.sub.0-a.sub.1-b.sub.1-c.sub.1-d.sub.1-e.sub.1-f.sub.1-g.sub.1-a.sub.2-b.sub.2-c.sub.2-d.sub.2-e.sub.2-f.sub.2-g.sub.2-a.sub.3-b.sub.3-c.sub.3-d.sub.3-e.sub.3-T.sub.2  (I)

T.sub.3-g′.sub.0-a′.sub.1-b′.sub.1-c′.sub.1-d′.sub.1-e′.sub.1-f′.sub.1-g′.sub.1-a′.sub.2-b′.sub.2-c′.sub.2-d′.sub.2-e′.sub.2-f′.sub.2-g′.sub.2-a′.sub.3-b′.sub.3-c′.sub.3-d′.sub.3-e′.sub.3-f′.sub.3-T.sub.4  (II),

as described in the present application. Methods of using these macrostructures are also disclosed.

This invention relates to macrostructures (and pharmaceutical formulations containing them) that include a parallel coiled-coil structure, wherein the parallel coiled-coil comprises a first coil of Formula I and a second coil of Formula II:

T.sub.1-f.sub.0-g.sub.0-a.sub.1-b.sub.1-c.sub.1-d.sub.1-e.sub.1-f.sub.1-g.sub.1-a.sub.2-b.sub.2-c.sub.2-d.sub.2-e.sub.2-f.sub.2-g.sub.2-a.sub.3-b.sub.3-c.sub.3-d.sub.3-e.sub.3-T.sub.2  (I)

T.sub.3-g′.sub.0-a′.sub.1-b′.sub.1-c′.sub.1-d′.sub.1-e′.sub.1-f′.sub.1-g′.sub.1-a′.sub.2-b′.sub.2-c′.sub.2-d′.sub.2-e′.sub.2-f′.sub.2-g′.sub.2-a′.sub.3-b′.sub.3-c′.sub.3-d′.sub.3-e′.sub.3-f′.sub.3-T.sub.4  (II),

as described in the present application. Methods of using these macrostructures are also disclosed.

A method for synthesizing a zirconium complex includes: mixing a solvent containing an organic substance having a dipole moment of 3.0 D or more, a chelating agent solution in which a chelating agent containing a structure represented by General Formula (1) or General Formula (2) is dissolved, and zirconium dissolved in an acidic solution, to obtain a mixed solution; and setting the mixed solution at a predetermined temperature or more to synthesize a zirconium complex.

##STR00001##

A method for synthesizing a zirconium complex includes: mixing a solvent containing an organic substance having a dipole moment of 3.0 D or more, a chelating agent solution in which a chelating agent containing a structure represented by General Formula (1) or General Formula (2) is dissolved, and zirconium dissolved in an acidic solution, to obtain a mixed solution; and setting the mixed solution at a predetermined temperature or more to synthesize a zirconium complex.

##STR00001##

16-membered macrolide compounds inhibit growth of various microbial species and have utility in the treatment of systemic or topical microbial infections, including methicillin-resistant strains (Formula I).

16-membered macrolide compounds inhibit growth of various microbial species and have utility in the treatment of systemic or topical microbial infections, including methicillin-resistant strains (Formula I).

Molybdenum(0) coordination complexes comprising ligands which each coordinate to the metal center by nitrogen or phosphorous are described. Methods for depositing molybdenum-containing films on a substrate are described. The substrate is exposed to a molybdenum precursor and a reactant to form the molybdenum-containing film (e.g., elemental molybdenum, molybdenum oxide, molybdenum carbide, molybdenum silicide, molybdenum nitride). The exposures can be sequential or simultaneous.

Aspects of the present disclosure include compounds that activate Nrf2. Such compounds find use in the treatment of autoimmune and inflammatory diseases and disorders, such as for example psoriasis and multiple sclerosis. Embodiments of the present disclosure also relate to pharmaceutical compositions that include these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Aspects of the present disclosure include compounds that activate Nrf2. Such compounds find use in the treatment of autoimmune and inflammatory diseases and disorders, such as for example psoriasis and multiple sclerosis. Embodiments of the present disclosure also relate to pharmaceutical compositions that include these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Provided are vitamin D.sub.3 derivatives of formula (I), pharmaceutical compositions thereof, and pharmaceutical or medical uses thereof for treating metabolic disease, a liver disease, obesity, diabetes, cardiovascular disease, or cancer in a patient in need thereof.